OGR

Lobbying for AMGEN USA INC

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $50,000.00 income · posted Jan 17, 2026

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare Part D and Medicare Part B reimbursement and coverage. Issues related to drug pricing. Issues related to biosimilar regulation.

Taxation/Internal Revenue Code

Issues related to Puerto Rico.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.